CL2020003133A1 - Formulación para uso en el tratamiento simultáneo de infecciones provocadas por coccidios y deficiencias de hierro - Google Patents

Formulación para uso en el tratamiento simultáneo de infecciones provocadas por coccidios y deficiencias de hierro

Info

Publication number
CL2020003133A1
CL2020003133A1 CL2020003133A CL2020003133A CL2020003133A1 CL 2020003133 A1 CL2020003133 A1 CL 2020003133A1 CL 2020003133 A CL2020003133 A CL 2020003133A CL 2020003133 A CL2020003133 A CL 2020003133A CL 2020003133 A1 CL2020003133 A1 CL 2020003133A1
Authority
CL
Chile
Prior art keywords
coccidia
formulation
infections caused
simultaneous treatment
iron deficiencies
Prior art date
Application number
CL2020003133A
Other languages
English (en)
Inventor
Kirsten Börngen
Stefan Hofmann
Maya Vinzing
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of CL2020003133A1 publication Critical patent/CL2020003133A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una formulación para su uso en el tratamiento simultáneo de infecciones provocadas por coccidios y deficiencias de hierro que contiene una triazinona como toltrazuril y un compuesto complejo polinuclear de polisacárido de hierro (III) junto con un tensioactivo seleccionado de manera específica que tiene un valor de equilibrio <br /> hidrofílico-lipofílico (HLB) ≥ 10.
CL2020003133A 2018-06-05 2020-12-02 Formulación para uso en el tratamiento simultáneo de infecciones provocadas por coccidios y deficiencias de hierro CL2020003133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18176138.8A EP3578181A1 (en) 2018-06-05 2018-06-05 Formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies

Publications (1)

Publication Number Publication Date
CL2020003133A1 true CL2020003133A1 (es) 2021-06-18

Family

ID=62567384

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003133A CL2020003133A1 (es) 2018-06-05 2020-12-02 Formulación para uso en el tratamiento simultáneo de infecciones provocadas por coccidios y deficiencias de hierro

Country Status (12)

Country Link
US (1) US20210228612A1 (es)
EP (2) EP3578181A1 (es)
JP (1) JP2021526148A (es)
KR (1) KR20210016548A (es)
CN (1) CN112423762A (es)
AU (1) AU2019280517A1 (es)
BR (1) BR112020024639A2 (es)
CA (1) CA3102068A1 (es)
CL (1) CL2020003133A1 (es)
MX (1) MX2020013082A (es)
PH (1) PH12020552058A1 (es)
WO (1) WO2019233870A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2740469A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale New treatments with triazines
EP2740470A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale Treatment of Coccidiosis with intramuscular triazine composition
CN113197915A (zh) * 2020-09-22 2021-08-03 湖北龙翔药业科技股份有限公司 右旋糖酐铁和帕托珠利的口服混悬液及其制备方法
CN113197849A (zh) * 2020-09-22 2021-08-03 湖北龙翔药业科技股份有限公司 含有葡庚糖酐铁和帕托珠利的混悬注射剂及其制备方法
CN113197850A (zh) * 2020-09-22 2021-08-03 湖北龙翔药业科技股份有限公司 葡庚糖酐铁和帕托珠利的口服混悬液及其制备方法
CN113209016A (zh) * 2020-09-22 2021-08-06 湖北龙翔药业科技股份有限公司 一种右旋糖酐铁和帕托珠利的混悬注射剂及其制备方法
CN116726045B (zh) * 2023-06-30 2024-03-19 重庆汉佩生物科技有限公司 一种氟雷拉纳组合物
CN116672360B (zh) * 2023-06-30 2024-05-14 重庆汉佩生物科技有限公司 一种妥曲珠利与葡庚糖酐铁的组合物
CN116712455B (zh) * 2023-06-30 2024-04-05 重庆汉佩生物科技有限公司 一种氟苯尼考与葡庚糖酐铁的组合物
CN116808072B (zh) * 2023-06-30 2024-02-20 重庆汉佩生物科技有限公司 一种抗虫组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2413722C3 (de) 1974-03-21 1982-04-08 Bayer Ag, 5090 Leverkusen Neue 1-(4-Phenoxy-phenyl)-1,3,5-triazin-Derivate, ein Verfahren zu ihrer Herstellung sowie ihre Anwendung als Arzneimittel
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
DE19824483A1 (de) 1998-06-02 1999-12-09 Bayer Ag Halbfeste wäßrige Zubereitungen für orale Applikation von Toltrazuril-Sulfon
DE10040174A1 (de) * 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
DE10040110A1 (de) * 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfoxiden zur Bekämpfung von Coccidiosen
DE102007025908A1 (de) 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
BR112015010253A2 (pt) 2012-11-06 2017-07-11 Rochal Ind Llc entrega de agentes biologicamente ativos com o uso de solventes hidrofóbicos e voláteis
EP2740492A1 (en) * 2012-12-07 2014-06-11 Ceva Sante Animale Triazine formulations with a second active ingredient and surfactant(s)
EP2740469A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale New treatments with triazines
EP2740470A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale Treatment of Coccidiosis with intramuscular triazine composition
DK3258920T3 (da) * 2015-02-17 2023-07-03 Univ Gent Fast farmaceutisk doseringsform, der er egnet til anvendelse som drikkevandsmedikament
CN108066767A (zh) * 2016-11-17 2018-05-25 北京科百大科技有限责任公司 一种稳定的含伊维菌素类药物的自乳化固体组合物

Also Published As

Publication number Publication date
PH12020552058A1 (en) 2021-07-05
EP3801541A1 (en) 2021-04-14
EP3578181A1 (en) 2019-12-11
JP2021526148A (ja) 2021-09-30
US20210228612A1 (en) 2021-07-29
MX2020013082A (es) 2021-03-02
KR20210016548A (ko) 2021-02-16
AU2019280517A1 (en) 2021-01-07
BR112020024639A2 (pt) 2021-03-02
CN112423762A (zh) 2021-02-26
CA3102068A1 (en) 2019-12-12
WO2019233870A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
CL2020003133A1 (es) Formulación para uso en el tratamiento simultáneo de infecciones provocadas por coccidios y deficiencias de hierro
MX2021005767A (es) Composiciones de nanoemulsiones que tienen una permeabilidad mejorada.
BR112017008499A2 (pt) métodos e composições relacionadas com o uso de tensoativos de baixo valor de hlb na produção de nanoportadores sintéticos compreendendo um rapalog
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2018013557A2 (es) Composiciones que comprenden cepas bacterianas
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CU20160187A7 (es) (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13, 13a-octahidro-2,5-metanopirido[1&#39;,2&#39;:4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio
AR108093A1 (es) Método y sistema para mezcla en línea de agente formador de espuma con modificadores de espuma para adición a suspensiones cementicias
CL2015003298A1 (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CL2009000721A1 (es) Combinacion que comprende un anticuerpo aislado anti-igf1r o un fragmento de fijacion de antigeno del mismo en asociacion con leucovorina y 5-fluorouracilo, leucovorina o sunitinib opcionalmente asociado con otro agente quimioterapeutico; y su uso para el tratamiento o prevencion del cancer colorectal.
CL2017000014A1 (es) Derivados de isondolina para su uso en el tratamiento de una infección viral
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
BR112016006112A2 (pt) aditivo para moagem de cimento para permitir uso de equipamento de pvc
AR113618A1 (es) Péptidos antimicrobianos y métodos para usarlos
CL2017002765A1 (es) El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de úlceras digitales (du) concomitante con esclerosis sistémica (ssc).
CL2017000563A1 (es) Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
AR104008A1 (es) Composiciones con propiedades de transferencia reducida de las tinturas
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
MX369223B (es) Composiciones de protector solar.
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
CL2022000492A1 (es) Proceso para la preparación de estetrol de alta pureza.
CO2019011300A2 (es) Composición de infliximab que contiene el sistema de tampón histidina
UY35824A (es) Preparación farmacéutica y forma de su producción y uso